12:00 AM
May 13, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Relistor methylnaltrexone regulatory update

Salix disclosed in its 1Q13 earnings that it submitted an appeal to FDA for a July 2012 complete response letter for an sNDA for subcutaneous Relistor methylnaltrexone to treat opioid-induced constipation (OIC) in patients with non-cancer...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >